Graph not available
Graph not available

Open Demat Account

50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Delivery and Volume
Similar Stocks

Shilpa Medicare Ltd Performance

Today's Low
Today's High
52 Wk Low
52 Wk High



Traded Value (Cr)


Prev. Close


Face Value




Shilpa Medicare Ltd Fundamentals

Market Cap
₹ 4906.17 Cr
P/E Ratio (TTM)
P/B Ratio
Debt to Equity
Dividend Yield
0.00 %
Book Value

Click here to know more about Fundamentals

Shilpa Medicare Ltd Financials

Shilpa Medicare Ltd Financials

Shilpa Medicare Ltd Shareholding Pattern

Held By Apr 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 44.39 % 50.01 % 50.01 % 50.01 %
Retail 24.54 % 27.65 % 25.45 % 25.40 %
Others 16.38 % 15.06 % 15.96 % 15.95 %
FII 9.68 % 5.69 % 8.52 % 8.60 %
Mutual Funds 5.01 % 1.59 % 0.06 % 0.04 %









Mutual Funds










Mutual Funds










Mutual Funds










Mutual Funds


Resistance and Support



First Resistance₹508.050
Second Resistance₹514.600
Third Resistance₹519.950
First Support₹496.150
Second Support₹490.800
Third Support₹484.250

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
1 Month37,943249,026-86.20
6 Months75,923,74232,602,67647.96

About Shilpa Medicare Ltd

Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SML's underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. SML's product range includes over 44 oncology and non-oncology APIs. The Company's formulation product range consists of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML's wholly owned subsidiary Shilpa Therapeutics Private Limited. SML deals in high-quality Active Pharmaceutical Ingredients (APIs), Bulk drug, Intermediates, Formulations and Development service, New Drug Delivery Systems, Peptides / Biotech products and Specialty Chemicals etc. using sophisticated technology meticulously in order to comply with laid down international standards/specifications. SML is among the world's leading suppliers of Oncology/Non-Oncology APIs and intermediates. In year 1992, the company installed production facilities to manufacture sodium methoxide. During FY 2015, projects of five products transfer executed successfully, other projects of eight products have been completed and ready for transfer to plant. Ten new molecules have been taken for development considering future demand. During FY15, as part of mobilization of resources for the purpose of expanding the operations of the Company, fresh funds were raised by allotting 17,64,705 equity shares of Rs.2/- each to Tano Mauritius India FVCI II, the existing member of the Company, at a premium of Rs 423/-each on 15 May 2014 on preferential basis. During FY2016, the company after obtaining the approval of members at the 28th Annual General Meeting held on 28 September, 2015, divided the face value of existing equity share of Rs.2/- into two equity shares of Re.1/- each fully paid-up, with effect from the Record Date specified. Raichem Medicare Pvt Ltd., a subsidiary of Shilpa Medicare, completed installation of all machineries during the FY 2015-2016 and recruited all the key personnel, also commenced trial production in August 2015 after the Audit by External Consultant from Italy and started commercial production in December-2015. The subsidiary obtained the Drug Manufacturing license and GMP certificate and consent from pollution control board for operating the plant. In FY 16-17, Shilpa Medicare launched the generic versions of Vidaza Injection & Xeloda Tablets. During the year under review, as part of mobilization of resources for the purpose of expanding the operations of the company, fresh funds were raised by allotting 30,25,000 equity shares of Re.1/- each to TA FII Investors Limited, at a premium of Rs.569/- each on 26 December, 2016 on preferential basis. Pursuant to the order dated 24 November 2017 of Hon'ble National Company Law Tribunal, Bangalore Bench, the Navya Biologicals Private Limited has been merged with the Company with effect from 1 April 2016 being the appointed date for merger. During the year 2019, an amount of Rs 22.71 crore was invested into its wholly owned subsidiary, Shilpa Therapeutics Pvt Ltd. (STPL) by way Loan to meet the project cost which is being set-up at Cherlapally, Telangana. During the year 2019, the Company disinvested 24% of stake in Raichem Medicare Private Limited, erstwhile Joint venture, and sold to Joint Venture Partner ICE S.p.A. In FY 2019, the company incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in United States of America. During the current FY 2019-20, the Company formed Sravathi Advance Process Technologies Private Limited to foray into the R&D activities of specific drug processes by roping prominent technocrats. It launched the Indian branded generic of Ibrutinib, an anti-cancer drug under the brand name 'IBRUSHIL'. During the financial year 2019-2020, Shilpa launched Azacitidine, covering the majority of European countries. It launched the first Indian Branded Generic of Lenvatinib Mesylate under the brand name Lenshil which is used for the treatment of differentiated thyroid cancer (DTC) and hepatocellular carcinoma. It sold 26% stake and exited from in Raichem Medicare Private Limited, erstwhile Joint Venture, in the month of June, 2020. It incorporated Shilpa Albumin Private Limited and Shilpa Biologicals Private Limited as Wholly Owned Subsidiaries of the Company. In 2021, the Company launched a pediatric dose paracetamol oral thin film, under the brand name 'Molshil' in strengths of 60 mg and 120 mg. It commissioned the State of Art Centralized Finished Dosages R&D Centre at Dabaspet near Bangalore. In 2021, Shilpa Biologicals Pvt Ltd, (SBPL), a wholly owned subsidiary of Company signed an agreement with Dr. Reddy's Laboratories for production-supply of Sputnik V vaccine from its integrated Biologics R&D cum manufacturing center at Dharwad, Karnataka. It formed Sravathi AI Technology Private Limited, Shilpa Corporate Holdings Private Limited and Koanna Helathcare, Cananda. In FY22 the Company received an approval from the Defence Research & Development Organization (DRDO) for the manufacture and sale of 2-DeoxyD-Glucose (2DG). It commissioned a combo line for ODF/TDS. During the year 2021-22, Shilpa Corporate holdings Private Limited an investment company, has been formed as a wholly owned subsidiary, which acquired 100% stake in FTF Pharma Private Limited an an integrated drug development company, Koanaa Healthcare Canada, Koanaa International FZ LLC (Dubai), Indo Biotech SDN. BHD Malaysia, and so that all these companies have become as wholly Owned Subsidiaries. Further, the Company acquired balance 25% equity shares of INM Technologies Private Limited and made a wholly owned subsidiary. INM Technologies Private Limited which is the wholly owned subsidiary of the Company holds 25% of its stake in INM Nuvent Paints Private Limited. The Company had disposed off the total stake in Loba Feinchemie Gmbh, a step down subsidiary in Austria. In year 2022, the Company launched 12 formulations in India. The new launches were in the therapeutic areas of oncology, non-oncology, and products for the OTC market such as women hygiene, vitamin supplements and an antioxidant green tea film. It commissioned new R&D center for polymer & peptide, created separate wing for CDM0 with its scientific head. In 2022, the Shareholders of the Company have approved the Slump sale of Active Pharmaceutical Ingredient (API) Business of the Company consisting of Unit-1 and Unit-2 situated at Raichur, Karnataka to its wholly owned subsidiary Shilpa Pharma Lifesciences Limited. The Company, has duly executed the Business Transfer agreement with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) which is complete and effective from 30 June 2022.

Managing Director



Vishnukant Bhutada

NSE Symbol


Shilpa Medicare Ltd Management

Omprakash InaniChairman (Non-Executive)
Vishnukant BhutadaManaging Director
Sharath Reddy KalakotaWhole-time Director
Arvind VasudevaIndependent Director
Hetal GandhiIndependent Director
Ritu TiwaryCompany Sec. & Compli. Officer
Kamal K SharmaIndependent Director
Anita BandyopadhyayIndependent Director

Shilpa Medicare Ltd News

Shilpa Medicare announces board meeting date
On 23 May 2024
Shilpa Medicare announces launch of PEMRYDI RTU®
By its marketing partner Amneal Pharmaceuticals
Shilpa Medicare rises after marketing partner launches pemetrexed formulation in US
Shilpa Medicare advanced 1.61% to Rs 549.15 after the company informed that its marketing partner, Amneal Pharmaceuticals, has launched 'PEMRYDI RTU’ (Pemetrexed injection), a ready-to-use pemetrexed formulation, in the US market.
Shilpa Medicare's Telangana facility gets Europe GMP Approval
Shilpa Medicare informed that its Unit 4, Jadcherla, Telangana facility has received EU good manufacturing practice (GMP) certificate.
Shilpa Medicare completes Rs 500-cr QIP issue of shares
The pharmaceutical company announced the completion of fundraising of Rs 500 crore through qualified institutional placement (QIP) of equity shares.
Shilpa Medicare allots 1.09 crore equity shares under QIP issue
Shilpa Medicare gains on launching QIP; floor price at Rs 477.33/share
Shilpa Medicare added 2.64% to Rs 518.55 after the company announced that its board approved the opening of qualified institutional placement (QIP) of equity shares with the floor price of Rs 477.33 per share.
Shilpa Medicare gains as Hyderabad unit clears USFDA inspection
Shilpa Medicare gained 1.33% to Rs 422.65 after the company informed that the United States Food and Drug Administration (USFDA) has closed its inspection without any 483 observation.
Shilpa Medicare gets Europe approval for Varenicline tablets
Shilpa Medicare announced that it has received Europe approval for closure of decentralized procedure for Varenicline tablets, 0.5 mg and 1 mg.
Shilpa Medicare receives Europe approval for Varenicline Tablets
Used to quit smoking

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 367554.12 Cr
₹ 1,531.90
(0.03 %)
Cipla Ltd₹ 113362.29 Cr
₹ 1,404.05
(0.36 %)
Zydus Lifesciences Ltd₹ 111083.2 Cr
₹ 1,103.95
(5.00 %)
Divis Laboratories Ltd₹ 104302.61 Cr
₹ 3,929.00
(0.47 %)
Dr Reddys Laboratories Ltd₹ 96948.1 Cr
₹ 5,811.60
(0.21 %)

Shilpa Medicare Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Shilpa Medicare Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Shilpa Medicare Ltd's share price is ₹501.50 as of May 18, 2024 at 01:44 PM

Shilpa Medicare Ltd's P/E ratio is 0.00 times as of May 18, 2024 at 01:44 PM.

Shilpa Medicare Ltd's most recent financial reports indicate a price-to-book ratio of 2.15, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Shilpa Medicare Ltd's market is 4,906 Cr as on May 18, 2024 at 01:44 PM.

The current financial records of Shilpa Medicare Ltd show a 3.49% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Shilpa Medicare Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

The 52-week high/low price of a Shilpa Medicare Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Shilpa Medicare Ltd's 52-week high and low as of May 18, 2024 at 01:44 PM are ₹561.6 and ₹561.6 respectively.

As of the Apr 2024 quarter, the promoter shareholding in Shilpa Medicare Ltd stands at 44.39%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 5.69% to 9.68%.